Cipla Harvard Case Solution & Analysis

The head of Cipla, $ 325-million Indian pharmaceutical company and seller of cheap AIDS drugs in South Africa, have to decide what to do with the future of Cipla's. With India ready to comply with international patents in two years, much of the product line Cipla could become unsaleable (given that it is based on the product is protected by patents in developed countries). Describes the role of a global pharmaceutical Cipla forcing companies to reduce the price of AIDS drugs. "Hide
by Rohit Deshpande, Laura Winig Source: Harvard Business School 21 pages. Publication Date: June 23, 2003. Prod. #: 503085-PDF-ENG

Share This

SALE SALE

Save Up To

30%

IN ONLINE CASE STUDY

FOR FREE CASES AND PROJECTS INCLUDING EXCITING DEALS PLEASE REGISTER YOURSELF !!

Register now and save up to 30%.